Seizure control status and associated factors among pediatric epileptic patients at a neurologic outpatient clinic in Ethiopia

Habtamu Digi Adal1, Kassahun Alemu2, Esileman Abdela Muche3

1 Department of Pharmacy, Teda Health Sciences College, Gondar, Ethiopia, 2 Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia, 3 Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

* sulamanab dela@gmail.com

Abstract

Background

Childhood epilepsy is a major public health problem worldwide. Even though anti-seizure medications (ASM) have been demonstrated to control seizures, children with epilepsy continue to have frequent seizures. There is a scarcity of data on seizure control status among pediatric epileptic patients in Ethiopia. The aim of this study was to assess seizure control status and associated factors among pediatric epileptic patients.

Methods

A hospital based cross-sectional study was done on 261 pediatric epileptic patients being followed up at the University of Gondar Comprehensive and Specialized Hospital, Northwest Ethiopia, from May 11 to August 11, 2019. The data were collected through caregiver interviews and patients’ medical records. All independent variables with p value of \( \leq 0.2 \) in univariate analysis were taken to multivariable analysis. Adjusted odds ratio (AOR) with a 95% confidence interval was computed to see the predictors of seizure control status. Level of statistical significance was declared if \( p \)-value < 0.05.

Result

From a total of 261 patients, 159 (60.9%) were males and had a mean age was 10.16 ± 4.62 years. More than half (57.1%) of participants were urban dwellers. Almost all (98.5%) were diagnosed with generalized tonic-clonic seizures. Majority (75.1%) of the patients were on mono-therapy. Forty-six (17.6%) of the patients reported adverse effects related to ASMs. Two hundred-three (77.8%) of the patients were adherent to their medications. Nearly half (49.0%) of the patients had controlled seizures. Urban residency (AOR: 2.12; 95% CI: 1.15–3.89; \( p = 0.016 \)), adherence to medication (AOR: 3.92; 95% CI: 1.84–8.36; \( p < 0.001 \)), use of combined ASM (AOR: 0.29; 95% CI: 0.14–0.59; \( p = 0.001 \)), durations of ASM use [2–5 years (AOR: 5.81; 95% CI: 2.89–11.70; \( p < 0.001 \)] and >5 years (AOR: 4.80; 95% CI: 1.91–12.09; \( p = 0.001 \)) were significantly associated with seizure control status.
Conclusion

Inadequate numbers of pediatric epileptic patients’ at the Ethiopian neurologic clinic achieved seizure control. Coming from a rural area, non-adherence to ASMs, use of multiple ASMs, and the use of ASMs for <2 years were found to have a significant association with poorer seizure control, needing special attention to get control of seizure. Caregivers should closely monitor and address any barriers that contribute to ASM non-adherence and adverse drug events.

Introduction

Epilepsy is the most common neurological disorder in children and a major public health problem worldwide. The seizures may start at any point during child’s lifetime and occur frequently [1]. The incidence of epilepsy is about 8 per 1,000 children below the age of 7 years. Around 5–10% of children suffer at least one seizure in the first 16 years of life. The incidence is highest in children below 3 years of age, with a decreasing frequency in older children. Studies reveal that globally nearly 150,000 children will sustain a first-time unprovoked seizure every year. From those, 30,000 will develop epilepsy [2]. The risk of premature death in children with epilepsy (CWE) is 5–10 times higher than in the general population. Global annual mortality rates range between 2.7 and 6.9 deaths per 1,000 CWE. In Africa, the childhood mortality rate is 92 per 1,000 live births; the distribution of deaths in CWE younger than 5 years of age is 33% in south Asia, 50% in sub-Saharan Africa, and less than 1% in high-income countries [3–6]. Around 2 in 5 children and adolescents with seizures have a learning disability and 20%–30% of them had an intellectual disability, attention deficit hyperactivity disorder and other developmental disorder. Nearly two third (65.5%) of CWE discontinue their school [7, 8]. Furthermore poorly controlled seizure leads to impaired quality of life, excessive bodily injury, impaired neuropsychological function, reduced marriage rates, poor education, reduced employment levels, reduced the capacity to participate in social activities, and shortened lifespan [9, 10]. Epilepsy in Ethiopia is also strongly associated with poor education and markers of poverty [11, 12].

Treatment with anti-seizure medication (ASM) is selected based on the type of seizure. The most recent recommendation is start ASMs either: after the second seizure or if the clinician believes that there is a >60% chance of the patient experiencing a second seizure, or if a diagnosis of an epileptic syndrome is made [13]. Treatment should be aimed at controlling seizures associated with the lowest possible overall cost and occurrence of adverse effects, thus allowing the child to become an active member of the community [14]. Although the number of ASMs increased globally and in Ethiopia, over 25% of CWE continue to have seizures [15]. ASMs fully control seizures in approximately 60% of children. The others 10–50% of children will gain good control of their seizures after a trial with second ASMs [16].

The seizure control capacity of ASM therapy in pediatrics patients depends on numerous factors, including, but not limited to, the availability and selections of ASMs, close monitoring of and the identification of underlying cause, the type of seizures, the pharmacokinetic parameters of ASMs, the caregiver’s knowledge, and attitude, and the level of adherence [8, 14].

Most of the previous studies in Ethiopia were carried out on adults with epilepsy, while the present study focused on CWE aged 1–18 years. Identifying factors that contribute to the seizure control status of CWE is very important and requires a deeper understanding. This helps
to develop new approaches to improve the utilization of health care services and seizure control. This study therefore aimed to describe the treatment outcomes of childhood epilepsy at University of Gondar Comprehensive and Specialized hospital (UoGCSH).

**Methods**

**Study area**

The study was conducted at the pediatric neurologic chronic outpatient department (OPD) clinic of UoGCSH, Northwest Ethiopia. The hospital is located in the Amhara National Regional State, 735 km away from Addis Ababa, the capital city of Ethiopia. It is one of the biggest tertiary-level teaching and referral hospitals in the region. The hospital serves more than seven million people in North Gondar and neighboring administrative zones. The catchment area comprises of rural and urban areas. The pediatric neurology clinic is an outpatient clinic that treats patients ≤18 years old. The clinic provides once weekly service (i.e. every Friday) to a total of 308 pediatrics epileptic patients on follow up basis. The health care providers at the paediatrics neurologic clinic includes one pediatric neurologist, 2–3 neurology residents, 3–4 intern physicians, and 2 nurses. The available resources for the diagnosis and treatment of epilepsy includes computed tomography (CT) scan, magnetic resonance imaging (MRI), electro encephalogram (EEG), random blood sugar and electrolyte tests.

**Study design and period**

The study was a hospital-based cross-sectional study conducted from May 11 to August 11, 2019.

**Population**

**Source population.**

- All pediatric epileptic patients attending the chronic follow-up clinic of UoGCSH

**Study population.**

- All pediatric epileptic patients attending the chronic follow-up clinic of UoGCSH and fulfilling the inclusion criteria during the study period.

**Inclusion and exclusion criteria**

**Inclusion criteria.**

- Patients of age ≤ 18 years and diagnosed to have epilepsy,
- Patients who were on ASMs for at least a year, and
- Patients whose caregivers were willing to give informed consent.

**Exclusion criteria.**

- Pediatric patients having seizures induced by drugs or due to any trauma or disease,
- Febrile seizure, and
- Unreadable and incomplete medical records were excluded from the study.
Sample size and sampling techniques
The total numbers of pediatrics epileptic patients on follow-up at the chronic outpatient clinic of UoGCSH were small (308) so; all eligible patients were included in this study. A total of 261 pediatrics epilepsy patients were included in the current study [17].

Data collection tool
Data was collected by using a structured questionnaire which contains three parts (S1 Text). Part I was about participant’s demography, while Part II contained questions regarding medication adherence and barriers for non-adherence. Part III contained questions about patient’s medical history and medication information. The questionnaire was first prepared in English and translated to Amharic (except part III), the local language, and then retranslated to English to ensure the consistency of the tool.

Medical and medication information were retrieved by reviewing each patient’s medical records using data extraction form (part III). The data extraction form contains the following information: the date of registration (hospital visit date), the date of ASMs initiation use, the patients’ age at the diagnosis of epilepsy, diagnosis or seizure type, patients follow up time, number of seizure episodes per month before ASMs used, seizure in the current follow up time, durations of seizure-free period, hospitalization or emergency care admission associated with epilepsy including seizure type/s, current ASM(s), number of ASMs, durations of ASMs used, any diagnosis other than epilepsy, any prescribed drugs other than ASM(s), and any adverse effect due to ASMs. The clinical information of the patients during the last one year also assessed.

Ten days before data collection, a pre-test was conducted on 15 pediatric epileptic patients on follow up at UoGCSH to ensure the completeness and consistency of the data collection tool. But those patients who participated in the pre-test were excluded from the main study.

Recruiting and training data collectors. Data were collected by two nurses and one general practitioner. The data collectors were trained about the objective of the study, and the methods of data collection including data extraction from patient charts as well as techniques of interviewing patients. The principal investigator (HDA) supervised the data collection throughout the process.

Data processing and analysis
The collected data were entered in to Epi-Info™ 7 software and cleaned, checked for its completeness, categorized, and coded. Then it was transferred to Statistical Package for the Social Science (SPSS Version 21.0) and was analyzed. Descriptive statistics were done for demographic and clinical details. The results were presented in the form of tables and graphs. Both bivariable and multivariable binary logistic regression analyses were done to see factors associated with seizure control status. All independent variables with \( p \) value \( \leq 0.2 \) in univariate analyses were taken to multivariable analysis to control for all the possible confounders.

Adjusted odds ratio (AOR) with a 95% confidence interval (CI) was computed to see the magnitude of association between seizure control status and the independent variables (gender, age, residence, education, adherence to ASMs, number of seizures before initiation ASMs, and the type and duration of ASM treatment). Level of statistical significance was set at \( p = \text{value of} < 0.05 \).

Ethical considerations
Ethical clearance was obtained from ethical review committee of the school of pharmacy of University of Gondar. Letter of cooperation was obtained from UoGCSH clinical directorate.
before going to neurology clinic. Moreover, written informed consent was obtained from each primary care giver of patients involved in the study and verbal assent were taken from the CWE. Furthermore, privacy and confidentiality of the information about the patients were ensured during primary care givers’ interviews and review of patients’ chart. The data was used for the study purpose only. And no personal identifying information was recorded in the data extraction formats.

Operational definition

Epilepsy was diagnosed clinically with history of two or more seizures that started in the brain with support of abnormal EEG finding [18]. In this study, the diagnosis of epilepsy is taken from each patient’s medical chart. Similarly, types of seizures were taken from the medical chart based on the EEG findings.

The seizure status was considered controlled if the patient had not experienced any seizure attacks in the past year, and not controlled if the patient experienced one or more seizure attacks in the last one year follow up period [19, 20].

Adherence was measured with pill count method where caregivers were asked to complete a questionnaire that helps to calculate the number of ASMs doses that were taken between appointments and comparing it with the total number of ASMS doses that the patient had received. = [(# of doses prescribed per follow up—# of doses missed per follow up)/# of doses prescribed per follow up]), which ranged from 0–100%. The patient was considered to be non-adherent if < 80% of prescribed pills were taken. On the other hand the patient who took > 80% of prescribed pill were considered to be adherent [21].

Results

Socio-demographic characteristics

A total of 261 patients were included in this study (Fig 1). The mean age of participants was 10.15 ± 4.6 years. The majority of the patients were males (60.9%), urban dwellers (57.1%), and Orthodox Christians (89.7%). Ninety percent of patients had no family history of epilepsy. More than half of the study participants (52.5%) were attending primary school at the time of data collection (Table 1).

Clinical characteristics

Among the study participants, nearly half (49.0%) of patients had controlled seizure. GTCS was the most common (98.5%) type of seizure. About three-fourths (75.1%) of the patients were on mono-therapy. Nearly half (47.5%) of participants had more than eight episodes of seizure per month before initiation of ASMs. Forty-six (17.6%) patients reported that they had experienced at least one adverse effect related to their ASMs therapy and 8 patients reported that they had more than one adverse drug effect: (weakness & irritability(n = 3), depressed mood & irritability(n = 2), headache & irritability(n = 1), depressed mood & headache (n = 1), epigastric pain & nightmare(n = 1)). Two hundred-three (77.8%) patients were adherent to their medications. The clinical characteristics of participants are summarized in Table 2.

A total of 58 (22.2%) patients were non adherent to their ASMs. The top three barriers for adherence were the child’s refusal to take the medicine 17(6.5%), lack of benefit 16(6.1), and forgetfulness to take medication 15(5.7%). The results are summarized in Table 3.
Factors associated with seizure control status

Bivariable logistic regression analysis did not show any association between seizure control and family history of epilepsy, health care payment, age at the diagnosis of epilepsy, follow up

Table 1. Socio-demographic characteristics of pediatric epileptic patients on follow-up at UoGCSH, Northwest Ethiopia, from May 11 to August 11, 2019 (N = 261).

| Variables                | Category           | Frequency n, (%) |
|--------------------------|--------------------|------------------|
| Gender                   | Female             | 102 (39.2%)      |
|                          | Male               | 159 (60.9%)      |
| Age                      | 1–5                | 58 (22.3%)       |
|                          | 5.1–10             | 64 (24.5%)       |
|                          | 10.1–15            | 105 (40.2%)      |
|                          | 15.1–18            | 34 (13.0%)       |
| Residency                | Urban              | 149 (57.1%)      |
|                          | Rural              | 112 (42.9%)      |
| Religion                 | Orthodox Christian | 234 (89.7%)      |
|                          | Islam              | 27 (10.3%)       |
| Family history           | No                 | 235 (90.0%)      |
|                          | Yes                | 26 (10.0%)       |
| Educational level        | Pre-school         | 114 (43.7%)      |
|                          | Primary school     | 137 (52.5%)      |
|                          | Secondary school   | 10 (3.8%)        |
| Health care payment method| Self               | 158 (60.5%)      |
|                          | Health insurance   | 103 (39.5%)      |
Table 2. Clinical characteristics of pediatric epileptic patients on follow-up at UoGCSH, Northwest Ethiopia, from May 11 to August 11, 2019 (N = 261).

| Variables                        | Category             | Frequency n, (%) |
|----------------------------------|----------------------|------------------|
| Age at diagnosis of epilepsy (years) | 0–5                  | 101 (38.7)       |
|                                  | 5.1–10               | 107 (41.0)       |
|                                  | 10.1–17              | 53 (20.3)        |
| Types of seizure                 | GTCS                 | 257 (98.5)       |
|                                  | Atonic Seizure       | 2 (0.8)          |
|                                  | Unclassified seizure | 2 (0.8)          |
| No of seizure episodes per month before ASMs used | 1–2                  | 76 (29.1)        |
|                                  | 3–5                  | 49 (18.8)        |
|                                  | 6–8                  | 12 (4.6)         |
|                                  | >8                   | 124 (47.5)       |
| Number of ASM(s) used            | Mono-therapy         | 196 (75.1)       |
|                                  | Combination therapy  | 65 (24.9)        |
| Type of ASM(s) used              | PHB                  | 107 (41.0)       |
|                                  | PHB+PHT              | 38 (14.6)        |
|                                  | PHB+VPA              | 18 (6.9)         |
|                                  | PHT                  | 71 (27.2)        |
|                                  | PHT+VPA              | 9 (3.4)          |
|                                  | VPA                  | 18 (6.9)         |
| Durations of ASMs used (years)   | 1–2                  | 89 (34.1)        |
|                                  | 2.1–5                | 117 (44.8)       |
|                                  | >5                   | 55 (21.1)        |
| Follow up time (appointment)     | Every One Month      | 172 (65.9)       |
|                                  | Every Two Months     | 73 (28.0)        |
|                                  | Every Three Months   | 16 (6.1)         |
| Seizure in the current follow up time | No                  | 186 (71.3)       |
|                                  | Yes                  | 75 (28.7)        |
| Seizure free years               | <1                   | 133 (51.0)       |
|                                  | 1–2.0                | 105 (40.2)       |
|                                  | 2.1–5                | 23 (8.8)         |
| Seizure control status           | Uncontrolled         | 133 (51.0)       |
|                                  | Controlled           | 128 (49.0)       |
| Diagnosis other than epilepsy    | No                   | 258 (98.9)       |
|                                  | Yes                  | 3 (1.1)          |
| Drugs prescribed other than ASMs | No                   | 259 (99.2)       |
|                                  | Yes                  | 2 (0.8)          |
| Adverse effects                  | No                   | 215 (82.4)       |
|                                  | Yes                  | 46 (17.6)        |
| Type of adverse effect (n = 54)  | Irritability         | 16 (29.6)        |
|                                  | Forgetfulness        | 8 (14.8)         |
|                                  | Gingival hyperplasia | 8 (14.8)         |
|                                  | Headache             | 6 (11.1)         |
|                                  | Depressed mood       | 6 (11.1)         |
|                                  | Confusion            | 3 (5.6)          |
|                                  | Weakness             | 3 (5.6)          |
|                                  | Epigastric pain      | 2 (3.7)          |
|                                  | Nightmare            | 1 (1.9)          |
|                                  | Skin rash            | 1 (1.9)          |

(Continued)
appointment period and adverse effect of ASMs. After adjusting for the above mentioned variables the final multivariable binary logistic regression analyses showed that urban residency (AOR: 2.12; 95% CI: 1.15–3.89), adherence (AOR: 3.92; 95% CI: 1.84–8.36), combined ASMs use (AOR: 0.29; 95% CI: 0.14–0.59), ASMs use for 2–5 years (AOR: 5.81; 95% CI: 2.89–11.70), and ASMs use for more than 5 years (AOR: 4.80; 95% CI: 1.91–12.09) were associated with seizure control (Table 4).

Discussion

In the current study, the overall treatment outcome revealed that nearly half (49.0%) of the participants had controlled seizures. This is lower than a study conducted in Ethiopia (77%) [22] Nigeria (64%) [20] and Norway (59.0%) [23]. The possible justification for this could be that the definition of controlled seizure in the other Ethiopian study was so broad that the result may be inflated (3 or fewer seizure during three month period). On the other hand differences in the time of initiating ASMs treatment, selections of ASMs, seizure type, cause of epilepsy, pharmaco-genomic factors, drug resistance and other associated factors that lead to poor response to treatment may contribute to the higher rates of controlled seizure in the Norwegian study [24].

Epileptic seizures were found to be more common in males (60.9%) than in females (39.1%). This is in line with a study done in Kenya [25]. Less than half of the patients (40.2%) belonged to the age group 10 to 15 years. This is different from the other studies carried out in Malaysia, Kenya and India in which a majority of children fall in the age group of 6 to 10 year [14, 25, 26].

The choice of the most suitable ASMs depends on the correct diagnosis of the seizure type. GTCS was the most common type of epileptic seizure encountered in 98.5% of patients. This

Table 2. (Continued)

| Variables          | Category   | Frequency n, (%) |
|--------------------|------------|------------------|
| Adherence status   | Non-adherent | 58 (22.2)        |
|                    | Adherent    | 203 (77.8)       |

GTCS, Generalized tonic clonic seizure; PHB, Phenobarbitone; PHT, Phenytoin; VPA, Valpuroic acid

https://doi.org/10.1371/journal.pone.0259079.t002

Table 3. Reasons for non adherence among pediatric epileptic patients on follow-up at UoGCSH, Northwest Ethiopia, from May 11 to August 11, 2019 (N = 93).

| Barriers for adherence                                      | Number of patient n (%) |
|------------------------------------------------------------|-------------------------|
| The child refuses to take the medicine                     | 17 (18.3%)              |
| Lack of benefit                                            | 16 (17.2%)              |
| Forget to take medication                                  | 15 (16.1%)              |
| Improvement and seizure free periods                       | 14 (15.1%)              |
| High frequency of medication                               | 14 (15.1%)              |
| Side effects of the medications                           | 7 (7.5%)                |
| Poor medication counseling                                 | 3 (3.2%)                |
| Embarrassed to take medicine in front of friends or family | 3 (3.2%)                |
| The pill is difficult for administration or difficult to swallow | 2 (2.2%)                |
| Child does not like the taste of medicine.                 | 1 (1.1%)                |
| High cost of medications                                  | 1 (1.1%)                |
| Total                                                      | 93 (100.0%)             |

https://doi.org/10.1371/journal.pone.0259079.t003
was higher than that was reported by studies done in India (55.0% and 55.2%), Malaysia (40.0%), and Ethiopia (48.6%) [14, 26–28]. The possible justification for this could be due to the difference in qualification of expertise and the diagnostic tools used, which can facilitate the classification of seizure type [29]. Also, low level of public awareness towards partial seizure, poor access to diagnostic imaging which helps health care providers to differentiate the seizure types, and lack of qualified experts in the study setting may all contribute to the observed differences with the other studies.

Table 4. Logistic regression analysis result of factors associated with seizure control status among pediatric epileptic patients at UoGCSH, Northwest Ethiopia, from May 11 to August 11, 2019 (N = 261).

| Variable                  | Category                     | Treatment outcome | COR (95% CI)      | AOR(95%CI)      | p-value |
|---------------------------|------------------------------|-------------------|-------------------|----------------|---------|
|                          |                              | Uncontrolled seizure n (%) | Controlled seizure n (%) |                     |         |
| *Gender                   | Female                       | 45 (44.1%)        | 57 (55.9%)        | 1               | 1       | 1       |
|                           | Male                         | 88 (55.3%)        | 71 (44.7%)        | 0.64 (0.39–1.05) | 0.66 (0.36–1.19) | 0.168   |
| *Age (years)             | 1–5.0                        | 39 (67.2%)        | 19 (32.8%)        | 1               | 1       | 1       |
|                           | 5.1–10.0                     | 32 (50.0%)        | 32 (50.0%)        | 2.05 (0.98–4.28) | 1.66 (0.61–4.50) | 0.322   |
|                           | 10.1–15.0                    | 43 (41.0%)        | 62 (59.0%)        | 2.96 (1.51–5.80) | 1.97 (0.69–5.60) | 0.206   |
|                           | 15.1–18                      | 19 (55.9%)        | 15 (44.1%)        | 1.62 (0.68–3.87) | 0.82 (0.20–3.39) | 0.787   |
| *Residence                | Urban                        | 68 (45.6%)        | 81 (54.4%)        | 1.65 (1.00–2.70) | 2.12 (1.15–3.89) | 0.016   |
|                           | Rural                        | 65 (58.0%)        | 47 (42.0%)        | 1               | 1       | 1       |
| *Education level          | Pre-school                   | 88 (55.3%)        | 71 (44.7%)        | 1               | 1       | 1       |
|                           | Primary School               | 45 (44.1%)        | 57 (55.9%)        | 2.58 (1.54–4.30) | 1.44 (0.65–3.17) | 0.366   |
|                           | Secondary School             | 4(40%)            | 6(60%)            | 2.67 (0.71–10.02) | 1.86(0.35–10.01) | 0.469   |
| *Adherence                | Non-adherence                | 42 (72.4%)        | 16 (27.6%)        | 1               | 1       | 1       |
|                           | Adherence                    | 91(44.8%)         | 112 (55.2%)       | 3.23 (1.71–6.12) | 3.92 (1.84–8.31) | <0.001   |
| *No of seizure episodes per month before ASMs used | 1–2                         | 28 (36.8%)        | 48 (63.2%)        | 1               | 1       | 1       |
|                           | 3–5                          | 24 (49.0%)        | 25 (51.0%)        | 0.61 (0.29–1.26) | 0.53 (0.22–1.28) | 0.159   |
|                           | 6–8                          | 7 (58.3%)         | 5 (41.7%)         | 0.42 (0.12–1.44) | 0.37 (0.09–1.54) | 0.173   |
|                           | >8                           | 74 (59.7%)        | 50 (40.3%)        | 0.39 (0.22–0.71) | 0.53 (0.26–1.09) | 0.083   |
| *Number of ASMs used      | Mono-therapy                 | 84 (42.9%)        | 112 (57.1%)       | 1               | 1       | 1       |
|                           | Combination therapy          | 49 (75.4%)        | 16 (24.6%)        | 0.25 (0.13–0.46) | 0.29 (0.14–0.59) | 0.001*  |
| *Durations of ASMs used (years) | 1–2                         | 63 (70.8%)        | 26 (29.2%)        | 1               | 1       | 1       |
|                           | 2–5                          | 44 (37.6%)        | 73 (62.4%)        | 4.02 (2.23–7.26) | 5.81 (2.89–11.70) | <0.001* |
|                           | >5                           | 26 (47.3%)        | 29 (52.7%)        | 2.70 (1.34–5.44) | 4.80 (1.91–12.09) | 0.001*  |

ASMs: Anti seizure medications, COR: Crude odds ratio AOR: Adjusted odds ratio, CI: Confidence interval
* Statistical significant association

https://doi.org/10.1371/journal.pone.0259079.t004
Multivariable binary logistic regression analysis revealed factors associated with seizure control status. Patients from urban area were 2.12 times more likely to have controlled seizure compared to patients from rural residence. Of those patients who live in urban areas, 54.4% of them had controlled seizure this could be explained by urban residents’ better awareness about the disease which facilitates a discussion with their health care professionals about the disease and the medications they use. In addition, most rural residents could be inclined to try religious and spiritual healing methods, reflecting the traditional thinking and beliefs about the disease [30, 31]. This condition is also bad in rural and remote areas where almost no services for epilepsy are accessible [5, 32].

Adherent patients were almost 4 times more likely to have controlled seizure than non-adherent patients. In agreement to this study, many studies have shown that adherence to medications improved the effectiveness of interventions [33]. Patients face different barriers that may contribute to their non-adherence. For this study, the top three barriers for adherence were the child’s refusal to take the medicine 17(6.5%), lack of benefit 16(6.1), and forgetfulness to take medication 15(5.7%). This finding is in line with the study conducted in Jordan [34], where the top 3 reasons for non-adherence were forgetfulness, children refusal to take medication and dissatisfaction with their medication.

Patients who used ASMs for 2 to 5 years duration were nearly 6 times more likely to have controlled seizure as compared to patients who took ASMs for 1 to 2 years. Patients who took ASMs for more than 5 years had 4.80 times more control seizure when compared with those patients who took ASMs for 1 to 2 years. Of those patients who used ASMs more than 5 years duration, 52.7% had controlled seizures and only 29.2% of patients who used ASMs for 1 to 2 years had controlled seizures. This shows that a longer duration of ASMs use associated with the seizure control status [35].

Patients who use combination therapy for their epilepsy had 71.0% less likely to have controlled seizure when compared with patients who were on mono-therapy. Of those patients who were on mono-therapy, 57.1% had controlled seizure and only 24.6% of combination therapy users had controlled seizures. In this finding, patients taking combination agents were less likely to control their seizure status. The lower level of adherence as a result of the prescription of multiple medications could contribute to the lower seizure control in patients on multiple ASMs when compared to those on monotherapy. In support of this justification adherence was shown to positively associate with seizure control status in this study. And most importantly, a patient with a more intractable epilepsy syndrome would be taking multiple ASMs [36].

Antiepileptic drug regimen is defined as a trial of either a single drug (mono-therapy) or a combination of two or more of ASMs treatment. Majority of patients with epilepsy respond to one of the first-line ASMs. Second-line drugs may be useful in patients who do not respond to one or a combination of the first-line ASMs [37, 38]. Mono-therapy was found to be the therapy of choice for majority of pediatric epileptic patients (75.1%) due to the fact that milder epilepsy only requires one agent. The findings of this study is in line with 2 studies conducted in India (71.0% and 73.5%), and less than what was reported in another study conducted in Ethiopia (88%) [26–28]. However, this is higher than study carried out in Malaysia (54.3%) [14]. The justification behind this could be, in Malaysia, health care professionals tend to prescribe more combination ASMs (45.7%) than what is reported in our setting (24.9%).

In the present study, phenobarbitone (41.0%) was found to be the most frequently prescribed drug as mono-therapy. The finding of the present study is different from studies done in different places, where carbamazepine and valproate were the most commonly prescribed ASMs in India [26, 39] and Malaysia [14], respectively. This could be due to long term use history, safety profile, availability, and affordability of phenobarbitone. WHO also recommends phenobarbitone as the first line drug for almost all types of seizure in developing countries.
including Ethiopia [1, 5]. Differences in country specific treatment guidelines could be the reason for differences in prescribing practices across different countries.

In this study, 17.6% of patients reported that they had experienced adverse effects related to their ASMs therapy. This result is lower than the finding from a study carried out in Singapore in which the adverse effects of ASMs were reported by 76.3% of participants [32]. The reasons behind this could be lower rate of pediatric ADRs reporting and inadequate public health programs for medicine safety monitoring in Ethiopia [40].

Limitation of the study

This study was done at single neurologic clinic North West part of Ethiopia with limited number of participants so it has potential limitation of generalizability of the work to Ethiopia as a whole. Also, the inclusion criteria state that patients must have been on ASMs for at least one year this is another potential limitation as the study population does not completely represent all people with epilepsy.

Conclusion

Nearly half of pediatrics epilepsy patients’ attending an Ethiopian neurologic clinic had controlled seizure. Patients who came from rural area, were non adherent to their ASMs use combination of ASMs, and were on ASMs for less than two years were found to have significant association with seizure control and need special attention to get their seizure controlled. The caregivers have crucial roles to play in monitoring and addressing the possible barriers for non-adherence and adverse drug events.

Supporting information

S1 Text. Data abstraction form.
(DOCX)

S1 Table. Reported side effect of ASMs among pediatric epileptic patients on follow-up at UoGCSH, Northwest Ethiopia, from May 11 to August 11, 2019 (N = 46).
(DOCX)

Acknowledgments

We would like to thank clinical pharmacy department for giving the chance to do this research. We are also very grateful to the nursing staffs of chronic outpatient department of UoGCSH for their cooperation in the data collection process.

Author Contributions

Conceptualization: Habtamu Digis Adal, Kassahun Alemu, Esileman Abdela Muche.
Data curation: Habtamu Digis Adal, Esileman Abdela Muche.
Formal analysis: Habtamu Digis Adal, Esileman Abdela Muche.
Methodology: Habtamu Digis Adal, Kassahun Alemu.
Project administration: Esileman Abdela Muche.
Software: Kassahun Alemu.
Supervision: Kassahun Alemu, Esileman Abdela Muche.
References

1. Website: www.who.int/mental_health/neurology/epilepsy/report_2019/en/

2. Preux PM, Druet-Cabana M. Epidemiology and etiology of epilepsy in sub-Saharan Africa. The Lancet Neurology. 2005 Jan 1; 4(1):21–31. https://doi.org/10.1016/S1474-4422(04)00963-9 PMID: 15620854

3. Wilmshurst JM, Kakooza-Mwesige A, Newton CR, editors. The challenges of managing children with epilepsy in Africa. Seminars in pediatric neurology. 2014. https://doi.org/10.1016/j.spen.2014.01.005 PMID: 24655403

4. Carpio A, Bharucha N, Jallon P, Beghi E, Camprostini R, Zorzetto S, et al. Mortality of epilepsy in developing countries. Epilepsia. 2005; 46:28–32. https://doi.org/10.1111/j.1528-1167.2005.00404.x PMID: 16393175

5. Organization WH. Epilepsy in the World Health Organization South-East Asian Region: Bridging the Gap. 2015.

6. Terra VC, Scorza FA, Arida RM, Fernandes RM, Wichert-Ana L, Machado HR, et al. Mortality in children with severe epilepsy: 10 years of follow-up. Arquivos de neuro-psiquiatria. 2011; 69(5):766–9. https://doi.org/10.1590/s0004-282x2011000600008 PMID: 22042178

7. Olusanya BO, Wright SM, Nair MK, Boo NY, Halpern R, Kuper H, et al. Global burden of childhood epilepsy, intellectual disability, and sensory impairments. Pediatrics. 2020 Jul 1; 146(1).

8. Minardi C, Minacapelli R, Valastro P, Vasile F, Pitino S, Pavone P, et al. Epilepsy in children: from diagnosis to treatment with focus on emergency. Journal of clinical medicine. 2019; 8(1):39. https://doi.org/10.3390/jcm8010039 PMID: 30609770

9. Niriayo YL, Mamo A, Kassa TD, Asgedom SW, Atey TM, Gidey K, et al. Treatment outcome and associated factors among patients with epilepsy. Scientific reports. 2018; 8(1):17354. https://doi.org/10.1038/s41598-018-35906-2 PMID: 30478263

10. MekonenTefera G, Woldehaimanot TE, Tarekegn M. Poor treatment outcomes and associated factors among epileptic patients at Ambo Hospital, Ethiopia. European journal of therapeutics. 2015; 21(1):9–16.

11. Vaid N, Fekadu S, Amnu S, Dessie A, Wabe G, Phillips DI, et al. Epilepsy, poverty and early under-nutrition in rural Ethiopia. Seizure. 2012 Nov 1; 21(9):734–9. https://doi.org/10.1016/j.seizure.2012.08.002 PMID: 22938819

12. Hassen O, Beyene A. The effect of seizure on school attendance among children with epilepsy: a follow-up study at the pediatrics neurology clinic, Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia. BMC pediatrics. 2020 Dec; 20:1–7.

13. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014 Apr; 55(4):475–82 https://doi.org/10.1111/epi.12550 PMID: 24730690

14. Hasan S, Bahari M, Babar Z, Ganesan V. Antiepileptic drug utilisation and seizure outcome among paediatric patients in a Malaysian public hospital. Singapore medical journal. 2010; 51(1):21. PMID: 20200771

15. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disorders. 2007; 9(4):353–412. PMID: 18077226

16. Laura Speltz MD, pediatric neurologist. Assessing First Seizures in Children and Adolescents. Pediatric Perspective. 2014; 23(1).

17. http://uregina.ca/~morrisev/Sociology/Sampling%20from%20small%20populations.htm

18. https://siapsprogram.org/publication/ethiopia-standard-treatment-guidelines

19. Dave H, Trivedi N. Drug utilization pattern of antiepileptic agents among paediatrics epilepsy at a tertiary care teaching hospital of Gujarat: A cross sectional study. Indian Journal of Basic and Clinical Pharmacology. 2018; 7(8):1606–1

20. Ejelogo EU, Uhunmwango-Courage A, Yiitok ES, Bok M. Short-term treatment outcome of childhood epilepsy in Jos, Nigeria. Journal of Medicine in the Tropics. 2020 Jul 1; 22(2):108.

21. Tailored Pharmacy-Based Interventions to Improve Medication Adherence | cdc.gov. https://www.cdc.gov/dhdsp/pubs/medication-adherence.htm
22. Beyene A, Ayalew AF, Mulat G, Simachew Kassa A, Birhan T. The treatment outcomes of epilepsy and its root causes in children attending at the University of Gondar teaching hospital: A retrospective cohort study, 2018. PloS one. 2020 Mar 12; 15(3):e0230187. https://doi.org/10.1371/journal.pone.0230187 PMID: 32163904

23. Aaberg KM, Bakken IJ, Lossius MI, Seraas CL, Tallur KK, Stoltenberg C, et al. Short-term seizure outcomes in childhood epilepsy. Pediatrics. 2018; 141(6):e20174016. https://doi.org/10.1542/peds.2017-4016 PMID: 29789444

24. Moosa AN. Antiepileptic drug treatment of epilepsy in children. 2019; 25(2):381–407.

25. Samia P, Barr A, Levi SB, Donald KA, Wilmshurst JM, Newton CR. Clinical characteristics of children with epilepsy managed at an urban hospital in Africa: a retrospective study. Journal of the International Child Neurology Association. 2019: 1

26. Hirenkumar H. Dave NAT. Drug utilization pattern of antiepileptic agents among pediatric epilepsy at tertiary care teaching hospital of Gujarat: a cross sectional study. IJBPC: International Journal of Basic & Clinical Pharmacology. 2018.

27. Arulkumaran K.S.G., S P, Rajasekaran A. A Study On Drug Use Evaluation Of Anti-Epileptics At A Multispecialty Tertiary Care Teaching Hospital. International Journal of PharmTech Research. 2009; 1(4).

28. Rishe W, Seifu MF, Gelaw BK, Gunasekaran T, Gebremariam ET, Mohammed MA. Drug use evaluation of antiepileptic drugs in outpatient epilepsy clinic of bishoftu general hospital, East Shoa, Ethiopia. Indo Am J Pharm Res. 2015; 5(2):951–62.

29. Excellence NIFC. Diagnosis and management of epilepsy in children and young people. 2007

30. Tekle-Haimanot R, Abebe M, Forsgren L, Gebre-Mariam A, Heijbel J, Holmgren G, et al. Attitudes of rural people in central Ethiopia toward epilepsy. Social science & medicine. 1991 Jan 1; 32(2):203–9.

31. Kpobi L, Swartz L, Keikelame MJ. Ghanaian traditional and faith healers’ explanatory models for epilepsy. Epilepsy & Behavior. 2018 Jul 1; 84:88–92. https://doi.org/10.1016/j.yebeh.2018.04.016 PMID: 29754110

32. Udaya PR, Rasika PA, Seetha T. Knowledge, attitude, and practice of epilepsy in rural Sri Lanka. BEA Trading Ltd Case reports in hematology. 2002

33. Organization WH. Improving adherence rates: Guidance for countries. Chapter V: The magnitude of the problem of poor adherence. 2003;2006.

34. Qoul KZ, Qasem DA, Samawi OH, Matter LN, Abo-tineh SI, Abo-olem M. Antiepileptic medication adherence in children with epilepsy at Queen Rania Al-Abdullah Children Hospital. Indian Journal of Medical Research and Pharmaceutical Sciences. 2015; 2(10).

35. Owolabi LF, Sale S, Owolabi SD. Clinico-electroencephalography pattern and determinant of 2-year seizure control in patients with complex partial seizure disorder in Kano, Northwestern Nigeria. Annals of medical and health sciences research. 2014; 4(2):186–91. PMID: 24761235

36. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. New England Journal of Medicine. 2003 Apr 10; 348(15):1442–8. https://doi.org/10.1056/NEJMoa021986 PMID: 12686700

37. Brodie M, Barry S, Bamagous G, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012; 78(20):1548–54. https://doi.org/10.1212/WNL.0b013e3182563b19 PMID: 22579629

38. Keith Howard LC, Rob Smith, Matthew O’Meara, Tomas Ratoni, Michael Cardamone, David Gleadhill, Darren Hawkes, Mansel Ismay. Infants and children—acute management of seizures. 2018:12–3.

39. Mistry Rusva A, S KC, Prajapati Hiren K., Doshi Tejas M., Trivedi Hiren R. Drug utilization pattern of antiseizure drugs and their adverse effects in the pediatric population, in a tertiary care hospital attached to a medical college. International Journal of Basic & Clinical Pharmacology. 2014; 3(2):336.

40. Birhane H, Islam M, Singh V. Pharmacovigilance: Adverse Drug Reactions (ADRs) in Pediatric patients in Ethiopia. Retrospective Study. Research Journal of Pharmacy and Technology. 2021 Mar 18; 14(3):1499–506